Citigroup Inc. Sells 29,083 Shares of Bruker Corporation $BRKR

Citigroup Inc. trimmed its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 32.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,838 shares of the medical research company’s stock after selling 29,083 shares during the quarter. Citigroup Inc.’s holdings in Bruker were worth $2,009,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of BRKR. Huntington National Bank boosted its stake in Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after buying an additional 645 shares in the last quarter. True Wealth Design LLC raised its stake in Bruker by 16,716.7% during the second quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock worth $42,000 after acquiring an additional 1,003 shares in the last quarter. Spire Wealth Management raised its stake in Bruker by 85.3% during the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after acquiring an additional 665 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Bruker by 79.7% during the third quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after acquiring an additional 1,230 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Bruker during the second quarter valued at $87,000. 79.52% of the stock is currently owned by institutional investors.

Bruker Trading Down 4.7%

Shares of NASDAQ BRKR opened at $36.68 on Monday. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $56.22. The company has a market cap of $5.58 billion, a PE ratio of -244.53, a P/E/G ratio of 2.20 and a beta of 1.19. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average of $44.68 and a two-hundred day moving average of $41.06.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). The company had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period last year, the company earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -133.33%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $6,319,395.60. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 27.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BRKR shares. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a report on Thursday, February 12th. Guggenheim boosted their price target on shares of Bruker from $53.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. UBS Group reaffirmed a “neutral” rating and set a $49.00 price objective on shares of Bruker in a research note on Friday, February 13th. TD Cowen dropped their price objective on shares of Bruker from $53.00 to $43.00 and set a “hold” rating for the company in a report on Friday, February 13th. Finally, Rothschild & Co Redburn set a $60.00 target price on shares of Bruker in a research note on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $50.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.